Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Market Cap ($4.03 Billion)
Market Cap & Net Worth: Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd market cap. Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (SHG:600332) has a market capitalization of $4.03 Billion (CN¥27.57 Billion) as of November 1, 2026. Listed on the SHG stock exchange, this China-based company holds position #3966 globally and #516 in its home market, demonstrating a 0.51% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's stock price CN¥19.61 by its total outstanding shares 1405890949 (1.41 Billion). Also see cash efficiency ratio of Guangzhou Baiyunshan Pharmaceutical Hold for how efficiently the company converts equity into cash flow.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Market Cap History (2015–2026)
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd market cap history from 2015 to 2026. Data shows change from $5.52 Billion to $4.03 Billion (-2.13% CAGR). Check current stock price of Guangzhou Baiyunshan Pharmaceutical Hold for real-time trading data and today's change.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 600332 net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.07x
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.78x
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's market cap is 1.78 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $4.42 Billion | $20.04 Billion | $1.51 Billion | 0.22x | 2.93x |
| 2017 | $5.99 Billion | $20.95 Billion | $2.06 Billion | 0.29x | 2.90x |
| 2018 | $6.72 Billion | $42.23 Billion | $3.44 Billion | 0.16x | 1.95x |
| 2019 | $6.76 Billion | $64.95 Billion | $3.19 Billion | 0.10x | 2.12x |
| 2020 | $5.65 Billion | $61.67 Billion | $2.92 Billion | 0.09x | 1.94x |
| 2021 | $6.73 Billion | $69.01 Billion | $3.72 Billion | 0.10x | 1.81x |
| 2022 | $5.99 Billion | $70.79 Billion | $3.97 Billion | 0.08x | 1.51x |
| 2023 | $5.88 Billion | $75.52 Billion | $4.06 Billion | 0.08x | 1.45x |
| 2024 | $5.85 Billion | $74.99 Billion | $2.84 Billion | 0.08x | 2.06x |
| 2025 | $5.30 Billion | $77.45 Billion | $2.98 Billion | 0.07x | 1.78x |
Competitor Companies of 600332 by Market Capitalization
Companies near Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd in the global market cap rankings as of November 1, 2026. Also see Guangzhou Baiyunshan Pharmaceutical Hold balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd by market ranking:
- McKesson Corporation (NYSE:MCK): Ranked #248 globally with a market cap of $101.38 Billion USD.
- Cencora Inc. (NYSE:COR): Ranked #451 globally with a market cap of $61.32 Billion USD.
- Cardinal Health Inc (NYSE:CAH): Ranked #626 globally with a market cap of $43.01 Billion USD.
- Sigma Healthcare Ltd (AU:SIG): Ranked #1151 globally with a market cap of $22.30 Billion USD ( AU$31.51 Billion AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #248 | McKesson Corporation | NYSE:MCK | $101.38 Billion | $994.58 |
| #451 | Cencora Inc. | NYSE:COR | $61.32 Billion | $330.84 |
| #626 | Cardinal Health Inc | NYSE:CAH | $43.01 Billion | $250.48 |
| #1151 | Sigma Healthcare Ltd | AU:SIG | $22.30 Billion | AU$2.73 |
Market Capitalization of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (2015–2026)
Market capitalization of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd from 2015 to today. Between 2015 and today, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's market cap moved from $5.52 Billion to $ 4.03 Billion, with a yearly change of -2.13%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥4.03 Billion | -23.82% |
| 2025 | CN¥5.30 Billion | -9.43% |
| 2024 | CN¥5.85 Billion | -0.63% |
| 2023 | CN¥5.88 Billion | -1.82% |
| 2022 | CN¥5.99 Billion | -10.94% |
| 2021 | CN¥6.73 Billion | +19.09% |
| 2020 | CN¥5.65 Billion | -16.47% |
| 2019 | CN¥6.76 Billion | +0.62% |
| 2018 | CN¥6.72 Billion | +12.30% |
| 2017 | CN¥5.99 Billion | +35.39% |
| 2016 | CN¥4.42 Billion | -19.85% |
| 2015 | CN¥5.52 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.03 Billion USD |
| MoneyControl | $4.03 Billion USD |
| MarketWatch | $4.03 Billion USD |
| marketcap.company | $4.03 Billion USD |
| Reuters | $4.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more